Active ingredients: brentuximab vedotin
What it is used for
Hodgkin lymphoma Treatment of adult patients with CD30+ Hodgkin Llymphoma (HL) at higher risk of relapse or progression following ASCT (see 5.1 Pharmacodynamic Properties, Clinical Trials). Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following autologous stem cell transplant (ASCT) or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Peripheral T-cell lymphoma Treatment of adult patients with previously untreated CD30+ peripheral T-cell lymphoma (PTCL) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP). Treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Cutaneous T cell lymphoma Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior Systemic therapy.
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- Shelf lifetime is 48 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
white to off-white lyophilized cake or powder
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient brentuximab vedotin
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems